key: cord-0780509-azmpd2kv
authors: Pawar, Anil; Pal, Amit
title: Molecular and functional resemblance of dexamethasone and quercetin: A paradigm worth exploring in dexamethasone‐nonresponsive COVID‐19 patients
date: 2020-09-30
journal: Phytother Res
DOI: 10.1002/ptr.6886
sha: 6630b65783dfff6057f3c59f49108b3f681ba88f
doc_id: 780509
cord_uid: azmpd2kv

nan

In addition to antiviral therapy, immunomodulatory drugs are also being used as treatment strategies to suppress hyperinflammation and to reduce death among COVID-19 patients (Mehta et al., 2020) . Corticosteroids have a long history of use in severe cases of coronavirus disease, including SARS, MERS, and COVID-19, as immunomodulatory drugs (Arabi et al., 2018; Huang et al., 2020; So et al., 2003) . Recently, dexamethasone (a synthetic adrenal corticosteroid), whose demand has surged suddenly after publication of the preprint paper of the RECOVERY trial (https://www.medrxiv.org/content/10.1101/2020. 06.22.20137273v1.full.pdf) , was found to be the first drug, which successfully reduced deaths in approximately one-third of critically ill F I G U R E 1 Schematic representation of possible antiinflammatory effects of quercetin against SARS-CoV-1/2. Quercetin has been demonstrated to inhibit SARS-CoV-1/2 entry inside cell by interfering with the expression of ACE2. Further, quercetin initiates IFN-γ production by T lymphocytes, which enhances anti-viral activity and antigen presentation by phagocytocytosis, and expression of MHC-I and MHC-II molecules. Decrement of inflammation and blood clotting in lungs is achieved by inhibition of IL-8 production by quercetin. Importantly, quercetin also inhibits the production of IL-4 and TNF-α, which helps in ameliorating inflammation. ACE2, Angiotensinconverting enzyme 2; IL, Interleukin; IFN-γ, Interferon-gamma; TNF-α, Tumor necrosis factor-alpha; SARS-CoV, Severe acute respiratory syndrome coronavirus [Colour figure can be viewed at wileyonlinelibrary.com] COVID-19 patients, who were on invasive mechanical ventilation support and by one-fifth in noninvasive ventilated patients. Interestingly, no positive outcome was reported from less severe COVID-19 patients, who were without any oxygen support. Likewise, in another randomized controlled trial (RCT), dexamethasone reduced mortality in ARDS patients (Villar et al., 2020) . The findings of Selvaraj, Dapaah-Afriyie, Finn, and Flanigan (2020) also support the use of dexamethasone in COVID-19 treatment, where the short-term course of dexamethasone prevented disease severity and in turn reduced the length of ICU stay of patients with hypoxic respiratory failure.

Dexamethasone, by suppressing the immune response, helps to overcome serious manifestations caused by the hyperactive immune response in COVID-19 patients. However, in the absence of adequate RCTs, there has always been controversy regarding the use of corticosteroids. The limiting element is the lack of standardization of various aspects, such as drug dose, route of administration, bioavailability, side effects and exact therapeutic impacts in patients. It has been observed that corticosteroid treatment prolonged the viral presence in SARS-CoV-1 patients (Lee et al., 2004) , and their administration in low doses had no impact on virus clearance in COVID-19 patients (Fang et al., 2020) . Because of several contradictory outcomes, it seems difficult to support the routine use of corticosteroids in COVID-19 disease management. Even existing guidelines of the World Health Organization (WHO) are not in favor of the routine use of corticoseroides in SARS-CoV-2 patients. In such a scenario, we searched for a suitable alternate option that can either augment or substitute dexamethasone action in dexamethasone-nonresponsive severely ill Covid-19 patients and for mild and moderate Covid-19 cases. At this point, it is imperative to discuss an interesting fact that Bhutto et al. (2018) identified molecular as well as functional similarity between dexamethasone and quercetin, [permeability-glycoprotein (P-gp) inducers]. P-gp, a membrane transporter, helps in the retention of various drugs, but pro-inflammatory cytokines released during infections have been observed to inhibit its expression and activity (Iqbal et al., 2012) . As P-gp inducers, both dexamethasone and quercetin, by interfering with p-gp expression, can inhibit the "cytokine Due to pleiotropic properties and capability to synergize with conventional drugs, it is assumed that flavonoids can reduce both transmembrane peptidase serine 2 (TMPRSS2) and Furin, which F I G U R E 2 Schematic representation of different stages of SARS-CoV-1 replication cycle inhibited by quercetin and zinc. Viral attachment (1), viral entry (2), preparation for viral uncoating (3), viral uncoating, and release of viral genome and viral protein (4), viral transcription (5), viral protein translation (6), viral replication (5), virus assembly and maturation (7) and, finally mature viral particles release (8). Quercetin has been demonstrated to inhibit SARS-CoV-1 entry (2) step, whereas, zinc inhibits SARS-CoV-1 genome transcription by inhibiting viral RdRp in a dose dependent manner(Step 5). ACE2, Angiotensin-converting enzyme 2; RdRp, RNA-dependent RNA polymerase; SARS-CoV, Severe acute respiratory syndrome coronavirus; Zn, zinc [Colour figure can be viewed at wileyonlinelibrary.com] cleave the SARS-CoV-2 Spike protein enabling SARS-CoV-2 infection (Russo, Moccia, Spagnuolo, Tedesco, & Russo, 2020) . Yi et al. (2004) specifically revealed that quercetin and another related flavonoid, luteolin, can inhibit the entry of SARS virus inside the host cell. Quercetin seems to impede the entry of SARS virus by targeting angiotensin-converting enzyme 2 (ACE2) expression (ACE2 gene expression is required for SARS-CoV-2 entry into human cells) ( Figure 1) (Glinsky, 2020) . Quercetin modulates the cellular unfolded protein response, which is utilized by viruses to complete its life cycle (Nabirotchkin, Peluffo, Bouaziz, & Cohen, 2020) . Study of Abian et al. (2020) is a direct evidence of quercetin's efficacy to target SARS-CoV-2 3C-like protease (3CLpro) on solid experimental bases.

In vitro studies have revealed the immunomodulatory effects of quercetin, which prevents the production of tumor necrosis factor-α in macrophages (Manjeet & Ghosh, 1999) and interleukin (IL)-8 production in lung cells (Geraets et al., 2007) . It is pertinent here to note that production of interferon-gamma (Th-1-derived cytokine) and the inhibition of IL-4 (Th-2-derived cytokine) may be responsible for the beneficial immunostimulatory effects of quercetin (Figure 1) (Nair et al., 2002) . Moreover, it is tempting to speculate that due to quercetin's zinc ionophore property, it along with zinc can be a potential 

Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening

Corticosteroid therapy for critically ill patients with middle east respiratory syndrome

The pharmacological activity, biochemical properties, and pharmacokinetics of the major natural polyphenolic flavonoid: Quercetin. Foods

Use of quercetin in animal feed: Effects on the P-gp expression and pharmacokinetics of orally administrated enrofloxacin in chicken

Antimicrobial activity of flavonoids

Lowdose corticosteroid therapy does not delay viral clearance in patients with COVID-19

Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells

Tripartite combination of candidate pandemic mitigation agents: Vitamin D, quercetin, and estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human cells

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Pro-inflammatory cytokine regulation of P-glycoprotein in the developing blood-brain barrier

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

Quercetin inhibits LPS-induced nitric oxide and tumor necrosis factor-alpha production in murine macrophages

COVID-19: Consider cytokine storm syndromes and immunosuppression

Focusing on the unfolded protein response and autophagy-related pathways to reposition commonly approved drugs against COVID-19

The flavonoid, quercetin, differentially regulates Th-1 (IFNgamma) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells

The role of zinc in antiviral immunity

Roles of flavonoids against coronavirus infection

Shortterm dexamethasone in sars-CoV-2 patients

Development of a standard treatment protocol for severe acute respiratory syndrome

Dietary quercetin supplements: Assessment of online product informations and quantitation of quercetin in the products by high-performance liquid chromatography

Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. The Lancet. Respiratory medicine

Histopathology and genetic susceptibility in COVID-19 pneumonia

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet

Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells

The authors duly acknowledge the NCBI, NIH and WHO for providing free online clinical trials/research articles/information related to